Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Int J Mol Sci
2014 Oct 09;1510:18148-61. doi: 10.3390/ijms151018148.
Show Gene links
Show Anatomy links
TPX2 is a prognostic marker and contributes to growth and metastasis of human hepatocellular carcinoma.
Huang Y
,
Guo W
,
Kan H
.
???displayArticle.abstract???
Targeting protein for Xenopus kinesin-like protein 2 (TPX2), a microtubule-associated protein, impacts spindle assembly in human cells. Several studies have demonstrated that TPX2 is overexpressed in different types of human cancers and promotes tumor growth and metastasis. In this study, we found that the expression level of TPX2 was obviously higher in hepatocellular carcinoma (HCC) tissues than in matched nontumor tissues. Elevated expressions of TPX2 mRNA were observed in all HCC cell lines (HepG2, Hep3B, SMMC-7721, Bel-7402 and Huh7) as compared with that in a non-transformed hepatic cell line (LO2). Clinical analysis indicated that the positive expression of TPX2 was significantly correlated with venous infiltration, high Edmondson-Steiner grading and advanced TNM tumor stage in HCC. Furthermore, TPX2 was a novel prognostic marker for predicting 5-year overall survival (OS) and disease-free survival (DFS) of HCC patients. In vitro studies found that TPX2 knockdown significantly inhibited cell proliferation and viability in both Hep3B and HepG2 cells. Moreover, TPX2 knockdown obviously slowed down tumor growth in a nude mouse xenograft model. Otherwise, TPX2 knockdown prominently suppressed HCC cell invasion and migration. In conclusion, these results indicate that TPX2 may serve as a prognostic marker and promotes tumorigenesis and metastasis of HCC.
Figure 1. The expression levels of TPX2 in hepatocellular carcinoma (HCC) tissues and cells. Comparing differences in the expression levels of TPX2 between (A) and (B) HCC (T) and matched nontumor tissues (NT) (n = 20), and (C) HCC cell lines and the immortalized hepatic cell line LO2 (n = 6). Values are depicted as Mean ± SEM; *
p < 0.05 by t test.
Figure 2. The immunostaining of TPX2 and its prognostic significance in HCC specimens. (A) Immunohistochemical staining of TPX2 in HCC. TPX2 was localized within the nuclei. Elevated expression of TPX2 (the arrows) in the tumor cells of HCC tissue (II, III, and IV) compared to normal tumor-adjacent tissues with negative staining (I) (scale bar: 100 μm); (B) The overall survival (OS) and (C) disease-free survival rates (DFS) were estimated by the Kaplan-Meier method. Both the OS rate and DFS rate of patients with TPX2 positive primary tumor were significantly lower than that of patients with TPX2 negative primary tumor (log-rank test, p < 0.05).
Figure 3. TPX2 knockdown inhibits cell proliferation and viability in HCC. (A) Hep3B and HepG2 cells that were transfected with non-targeting (NT) shRNA and TPX2 shRNA, respectively, were subjected to WB for TPX2. n = 6; *
p < 0.05 by t test; (B) Cell proliferation as measured by BrdU incorporation was inhibited by TPX2 knockdown in Hep3B and HepG2 cells. *
p < 0.05 by t test; n = 3 repeats with similar results; (C) As assessed by MTT assays, TPX2 knockdown was found to reduce the viability of Hep3B and HepG2 cells. *
p < 0.05 by two-way ANOVA; n = 3 repeats with similar results. Values are depicted as Mean ± SEM.
Figure 4. TPX2 knockdown suppresses tumor growth in mice. (A) Hep3B cells that were transfected with NT shRNA or TPX2 shRNA were implanted into nude mice through subcutaneous injection. Tumor growth curves indicated that TPX2 knockdown Hep3B cells (n = 6) exhibited a greater tumor-inhibiting effect compared with control cells (n = 6). Scale bar: 100 μm; *
p < 0.05 by two-way ANOVA; (B) Tumor nodules were subjected to immunohistochemical staining for Ki-67 and quantitative analysis. Representative immunostaining of Ki-67 (the arrows) revealed that TPX2 knockdown significantly reduced the number of Ki-67 positive cells. Scale bar: 100 μm; n = 6; *
p < 0.05 by t test.
Figure 5. TPX2 knockdown inhibits HCC cell migration and invasion. Cell migration as measured by Boyden chamber assays was inhibited by TPX2 knockdown in Hep3B and HepG2 cells as compared with control cells. TPX2 down-regulating Hep3B and HepG2 cells conferred a less number of invaded cells as compared with control cells. n = 6 repeats with similar results; *
p < 0.05 by t test. Values are depicted as Mean ± SEM.
Aguirre-Portolés,
Tpx2 controls spindle integrity, genome stability, and tumor development.
2012,
Pubmed
Bruix,
Management of hepatocellular carcinoma: an update.
2011,
Pubmed
Cáceres-Gorriti,
RAN nucleo-cytoplasmic transport and mitotic spindle assembly partners XPO7 and TPX2 are new prognostic biomarkers in serous epithelial ovarian cancer.
2014,
Pubmed
Chang,
The TPX2 gene is a promising diagnostic and therapeutic target for cervical cancer.
2012,
Pubmed
Ferlay,
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
2010,
Pubmed
Friedman,
Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
2004,
Pubmed
Gruss,
Chromosome-induced microtubule assembly mediated by TPX2 is required for spindle formation in HeLa cells.
2002,
Pubmed
,
Xenbase
Heidebrecht,
p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M.
1997,
Pubmed
Hsu,
TPX2 expression is associated with cell proliferation and patient outcome in esophageal squamous cell carcinoma.
2014,
Pubmed
Jiang,
TPX2 regulates tumor growth in human cervical carcinoma cells.
2014,
Pubmed
,
Xenbase
Kufer,
Human TPX2 is required for targeting Aurora-A kinase to the spindle.
2002,
Pubmed
,
Xenbase
Li,
Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients.
2013,
Pubmed
Li,
SREBP-1 has a prognostic role and contributes to invasion and metastasis in human hepatocellular carcinoma.
2014,
Pubmed
Liu,
Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamous cell carcinoma.
2013,
Pubmed
Neumayer,
TPX2: of spindle assembly, DNA damage response, and cancer.
2014,
Pubmed
Satow,
Combined functional genome survey of therapeutic targets for hepatocellular carcinoma.
2010,
Pubmed
Shigeishi,
Expression of TPX2 in salivary gland carcinomas.
2009,
Pubmed
Tu,
Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma.
2012,
Pubmed
Tu,
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
2014,
Pubmed
Tu,
Prognostic significance of miR-218 in human hepatocellular carcinoma and its role in cell growth.
2014,
Pubmed
Tu,
Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E.
2013,
Pubmed
Vainio,
High-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancer.
2012,
Pubmed
Warner,
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells.
2009,
Pubmed
Wei,
TPX2 is a novel prognostic marker for the growth and metastasis of colon cancer.
2013,
Pubmed
Wittmann,
TPX2, A novel xenopus MAP involved in spindle pole organization.
2000,
Pubmed
,
Xenbase
Yan,
Target protein for Xklp2 (TPX2), a microtubule-related protein, contributes to malignant phenotype in bladder carcinoma.
2013,
Pubmed
